IRIS Accounts Production v24.3.2.46 11254290 Board of Directors 31.3.23 30.3.24 30.3.24 false true false false true false Fair value model Ordinary Share A 1.00000 Ordinary Share B 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh112542902023-03-30112542902024-03-30112542902023-03-312024-03-30112542902022-03-31112542902022-04-012023-03-30112542902023-03-3011254290ns15:EnglandWales2023-03-312024-03-3011254290ns14:PoundSterling2023-03-312024-03-3011254290ns10:Director12023-03-312024-03-3011254290ns10:PrivateLimitedCompanyLtd2023-03-312024-03-3011254290ns10:SmallEntities2023-03-312024-03-3011254290ns10:AuditExempt-NoAccountantsReport2023-03-312024-03-3011254290ns10:SmallCompaniesRegimeForDirectorsReport2023-03-312024-03-3011254290ns10:SmallCompaniesRegimeForAccounts2023-03-312024-03-3011254290ns10:FullAccounts2023-03-312024-03-3011254290ns10:OrdinaryShareClass12023-03-312024-03-3011254290ns10:OrdinaryShareClass22023-03-312024-03-3011254290ns10:Director22023-03-312024-03-3011254290ns10:Director32023-03-312024-03-3011254290ns10:Director42023-03-312024-03-3011254290ns10:RegisteredOffice2023-03-312024-03-3011254290ns5:CurrentFinancialInstruments2024-03-3011254290ns5:CurrentFinancialInstruments2023-03-3011254290ns5:ShareCapital2024-03-3011254290ns5:ShareCapital2023-03-3011254290ns5:RetainedEarningsAccumulatedLosses2024-03-3011254290ns5:RetainedEarningsAccumulatedLosses2023-03-3011254290ns5:WithinOneYearns5:CurrentFinancialInstruments2024-03-3011254290ns5:WithinOneYearns5:CurrentFinancialInstruments2023-03-3011254290ns10:OrdinaryShareClass12024-03-3011254290ns10:OrdinaryShareClass22024-03-30
REGISTERED NUMBER: 11254290 (England and Wales)










Kinsella Holdings Limited

Unaudited Financial Statements

for the Year Ended 30 March 2024






Kinsella Holdings Limited (Registered number: 11254290)






Contents of the Financial Statements
for the Year Ended 30 March 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


Kinsella Holdings Limited

Company Information
for the Year Ended 30 March 2024







DIRECTORS: Mr MJ Kinsella
Mrs B Kinsella
Mr E Kinsella
Mr R Kinsella





REGISTERED OFFICE: 31 Sackville Street
Manchester
M1 3LZ





REGISTERED NUMBER: 11254290 (England and Wales)






Kinsella Holdings Limited (Registered number: 11254290)

Balance Sheet
30 March 2024

2024 2023
Notes £    £   
FIXED ASSETS
Investments 5 599 599

CURRENT ASSETS
Debtors 6 519,538 437,674

CREDITORS
Amounts falling due within one year 7 (519,451 ) (380,374 )
NET CURRENT ASSETS 87 57,300
TOTAL ASSETS LESS CURRENT
LIABILITIES

686

57,899

CAPITAL AND RESERVES
Called up share capital 8 110 110
Retained earnings 576 57,789
SHAREHOLDERS' FUNDS 686 57,899

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 March 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 March 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 28 March 2025 and were signed on its behalf by:



Mr MJ Kinsella - Director


Kinsella Holdings Limited (Registered number: 11254290)

Notes to the Financial Statements
for the Year Ended 30 March 2024

1. GENERAL INFORMATION

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
31 Sackville Street
Manchester
M1 3LZ
England

2. STATEMENT OF COMPLIANCE

These financial statements have been prepared in accordance with Financial Reporting Standard 102
Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

3. ACCOUNTING POLICIES

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND KEY ACCOUNTING ESTIMATES
The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

BASIS OF PREPARATION
These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

TAX
The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

BUSINESS COMBINATIONS
Business combinations are accounted for using the purchase method. The consideration for each acquisition is measured at the aggregate of the fair values at acquisition date of assets given, liabilities incurred or assumed, and equity instruments issued by the group in exchange for control of the acquired, plus any costs directly attributable to the business combination. When a business combination agreement provides for an adjustment to the cost of the combination contingent on future events, the group includes the estimated amount of that adjustment in the cost of the combination at the acquisition date if the adjustment is probable and can be measured reliably.

INVESTMENTS
Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.

Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.






Kinsella Holdings Limited (Registered number: 11254290)

Notes to the Financial Statements - continued
for the Year Ended 30 March 2024

TRADE DEBTORS
Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

TRADE CREDITORS
Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

SHARE CAPITAL
Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

4. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 4 (2023 - 4 ) .

5. INVESTMENTS
Total
£   
FAIR VALUE
At 31 March 2023
and 30 March 2024 599
NET BOOK VALUE
At 30 March 2024 599
At 30 March 2023 599

Details of the investments in which the company holds 20% or more of the nominal value of any class of
share capital are as follows:



Undertaking


Registeredoffice


Holding
Proportion of
votingrights and shares
held
Subsidiary undertakings20242023
Re-Enhance LimitedEngland Ordinary49% 49%
EM Pharma LimitedEngland Ordinary100%100%
Kinsella Aesthetics Limited England Ordinary100%100%
Kinsella Training LimitedEngland Ordinary100%100%
Re-Enhance Cosmetics LimitedEngland Ordinary90% 90%
BioID Hormones LimitedEngland Ordinary100%100%

Kinsella Holdings Limited (Registered number: 11254290)

Notes to the Financial Statements - continued
for the Year Ended 30 March 2024

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Other debtors 519,538 437,674

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Taxation and social security 28,112 41,305
Other creditors 491,339 339,069
519,451 380,374

8. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
100 Ordinary Share A 1 100 100
10 Ordinary Share B 1 10 10
110 110

9. RELATED PARTY TRANSACTIONS

The company was under the control of Dr M Kinsella, who holds 68% of the company's share capital.

At the balance sheet date, the amounts owed to the directors of the company stood at £4,427 (2023: £9,461 cr).

Dividends paid to shareholders during the year amounted to £331,000 (2023: £362,000).

At the balance sheet date, the amount owing to Re-Enhance Ltd stood at £482,436 (2023: £329,487).
There was an additional £374,462 owing from EM Pharma Ltd (2023: £258,874), as well as a balance of £145,076 (2022: £178,800) owing from Kinsella Aesthetics Limited.

Dividend income from subsidiaries during the year amounted to £217,500 (2023: £258,000).

Management charge income from subsidiaries during the year amounted to £80,000 (2023: £80,000).